Skip to main content

Advertisement

SpringerLink
Log in

The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer

  • Review
  • Published:
Inflammation Research Aims and scope Submit manuscript

Abstract

Background

Platelet-to-lymphocyte (PLR) and Neutrophil-to-Lymphocyte (NLR) ratios have been extensively investigated in cancer. However, to date, actual guidelines concerning ovarian cancer are missing. The purpose of the present systematic review is to summarize the available evidence.

Methods

We systematically searched Medline (1966–2016), Scopus (2004–2016), ClinicalTrials.gov (2008–2016), and Cochrane Central Register of Controlled Trials CENTRAL (1999–2016) databases together with reference lists from included studies.

Results

Eighteen studies were included in the present systematic review that involved 3453 patients. According to the current data, both PLR and NLR values in ovarian cancer patients seem to deviate from healthy controls. Furthermore, they may also be indicative of the stage of the disease and of the response to chemotherapy. Nevertheless, their diagnostic accuracy remains limited as their sensitivity and specificity are moderate (detects 55–80% of ovarian cancer women).

Conclusion

According to the findings of our study, both PLR and NLR seem to be promising screening and prognostic factors of epithelial ovarian cancer. The actual diagnostic cut-off values remain, however, undefined until now. Despite their limited sensitivity and specificity, they might be useful in the future as adjunct biomarkers for the detection and surveillance of the disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86. doi:10.1002/ijc.29210.

    Article  CAS  PubMed  Google Scholar 

  2. Society AC. American Cancer Society: Cancer Facts and Figs. 2012. American Cancer Society Atlanta, GA; 2012.

  3. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol. 1983;61(4):413–20.

    CAS  PubMed  Google Scholar 

  4. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19(4):1001–7.

    Article  CAS  PubMed  Google Scholar 

  5. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6. doi:10.1056/nejm199601043340101.

    Article  CAS  PubMed  Google Scholar 

  6. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068–75.

    Article  CAS  PubMed  Google Scholar 

  7. Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56. doi:10.1016/s0140-6736(15)01224-6.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Moyer VA. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157(12):900–4. doi:10.7326/0003-4819-157-11-201212040-00539.

    Article  PubMed  Google Scholar 

  9. Canney PA, Moore M, Wilkinson PM, James RD. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984;50(6):765–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Todoric J, Antonucci L, Karin M. Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res. 2016;9(12):895–905. doi:10.1158/1940-6207.capr-16-0209.

  11. Li QQ, Lu ZH, Yang L, Lu M, Zhang XT, Li J, et al. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy. Asian Pac J Cancer Prev. 2014;15(2):945–50.

    Article  PubMed  Google Scholar 

  12. Shen J, Zhu Y, Wu W, Zhang L, Ju H, Fan Y, et al. Prognostic role of Neutrophil-to-Lymphocyte ratio in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Med Sci Monit. 2017;23:315–24.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Oncel M, Kiyici A, Oncel M, Sunam GS, Sahin E, Adam B. Evaluation of platelet indices in lung cancer patients. Asian Pac J Cancer Prev. 2015;16(17):7599–602.

    Article  PubMed  Google Scholar 

  14. Jung J, Park SY, Park SJ, Park J. Prognostic value of the neutrophil-to-lymphocyte ratio for overall and disease-free survival in patients with surgically treated esophageal squamous cell carcinoma. Tumour Biol. 2016;37(6):7149–54. doi:10.1007/s13277-015-4596-3.

    Article  PubMed  Google Scholar 

  15. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695–9. doi:10.1038/bjc.2012.292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Xiang J, Zhou L, Li X, Bao W, Chen T, Xi X, et al. Preoperative Monocyte-to-Lymphocyte ratio in peripheral blood predicts stages, metastasis, and histological grades in patients with ovarian cancer. Transl Oncol. 2016;10(1):33–9. doi:10.1016/j.tranon.2016.10.006.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. doi:10.1016/j.jclinepi.2009.06.006.

    Article  PubMed  Google Scholar 

  18. Banerjee S, Rustin G, Paul J, Williams C, Pledge S, Gabra H, et al. A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Ann Oncol. 2013;24(3):679–87. doi:10.1093/annonc/mds494.

    Article  CAS  PubMed  Google Scholar 

  19. Eo WK, Chang HJ, Kwon SH, Koh SB, Kim YO, Ji YI, et al. The Lymphocyte-Monocyte ratio predicts patient survival and aggressiveness of ovarian cancer. J Cancer. 2016;7(3):289–96. doi:10.7150/jca.13432.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Medina Fernandez FJ, Munoz-Casares FC, Arjona-Sanchez A, Casado-Adam A, Gomez-Luque I, Garcilazo Arismendi DJ, et al. Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC. Ann Surg Oncol. 2015;22(4):1332–40. doi:10.1245/s10434-014-4096-5.

    Article  CAS  PubMed  Google Scholar 

  21. Watanabe T, Shibata M, Nishiyama H, Soeda S, Furukawa S, Gonda K, et al. Serum levels of rapid turnover proteins are decreased and related to systemic inflammation in patients with ovarian cancer. Oncol Lett. 2014;7(2):373–7. doi:10.3892/ol.2013.1735.

    PubMed  Google Scholar 

  22. Kim SI, Kim HS, Kim TH, Suh DH, Kim K, No JH, et al. Impact of underweight after treatment on prognosis of advanced-stage ovarian cancer. J Immunol Res. 2014;2014:349546. doi:10.1155/2014/349546.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Nakamura K, Nagasaka T, Nishida T, Haruma T, Ogawa C, Kusumoto T, et al. Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. Oncol Lett. 2016;11(6):3975–81. doi:10.3892/ol.2016.4513.

    PubMed  PubMed Central  Google Scholar 

  24. Seckin KD, Karsli MF, Yucel B, Bestel M, Yildirim D, Canaz E, et al. The utility of tumor markers and neutrophil lymphocyte ratio in patients with an intraoperative diagnosis of mucinous borderline ovarian tumor. Eur J Obstet Gynecol Reprod Biol. 2016;196:60–3. doi:10.1016/j.ejogrb.2015.10.025.

    Article  CAS  PubMed  Google Scholar 

  25. Polat M, Senol T, Ozkaya E, Ogurlu Pakay G, Cikman MS, Konukcu B, et al. Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion. Clin Transl Oncol. 2016;18(5):457–63. doi:10.1007/s12094-015-1387-7.

    Article  CAS  PubMed  Google Scholar 

  26. Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, et al. Roles of neutrophil/lymphocyte and platelet/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pac J Cancer Prev. 2014;15(16):6881–5.

    Article  PubMed  Google Scholar 

  27. Bakacak M, Serin S, Ercan O, Kostu B, Bostanci MS, Bakacak Z, et al. Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses. J Turk Ger Gynecol Assoc. 2016;17(1):21–5. doi:10.5152/jtgga.2015.0152.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Ozaksit G, Tokmak A, Kalkan H, Yesilyurt H. Value of the platelet to lymphocyte ratio in the diagnosis of ovarian neoplasms in adolescents. Asian Pac J Cancer Prev. 2015;16(5):2037–41.

    Article  PubMed  Google Scholar 

  29. Kemal Y, Demirag G, Ekiz K, Yucel I. Mean platelet volume could be a useful biomarker for monitoring epithelial ovarian cancer. J Obstet Gynaecol. 2014;34(6):515–8. doi:10.3109/01443615.2014.912620.

    Article  CAS  PubMed  Google Scholar 

  30. Kokcu A, Kurtoglu E, Celik H, Tosun M, Malatyalioglu E, Ozdemir AZ. May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? Asian Pac J Cancer Prev. 2014;15(22):9781–4.

    Article  PubMed  Google Scholar 

  31. Kim HS, Choi HY, Lee M, Suh DH, Kim K, No JH, et al. Systemic inflammatory response markers and CA-125 levels in ovarian clear cell carcinoma: a two center cohort study. Cancer Res Treat. 2016;48(1):250–8. doi:10.4143/crt.2014.324.

    Article  CAS  PubMed  Google Scholar 

  32. Badora-Rybicka A, Nowara E, Starzyczny-Słota D. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. 2016;1(2):e000039.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Williams KA, Labidi-Galy SI, Terry KL, Vitonis AF, Welch WR, Goodman A, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014;132(3):542–50. doi:10.1016/j.ygyno.2014.01.026.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. J Gynecol Oncol. 2012;23(4):265–73. doi:10.3802/jgo.2012.23.4.265.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15–23. doi:10.1007/s00262-008-0516-3.

    Article  CAS  PubMed  Google Scholar 

  36. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13(7):499–503. doi:10.1007/s12094-011-0687-9.

    Article  PubMed  Google Scholar 

  37. Wang Y, Liu P, Xu Y, Zhang W, Tong L, Guo Z, et al. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. Cancer Chemother Pharmacol. 2015;75(2):255–62. doi:10.1007/s00280-014-2622-6.

    Article  CAS  PubMed  Google Scholar 

  38. Bednarska K, Klink M, Wilczynski JR, Szyllo K, Malinowski A, Sulowska Z, et al. Heterogeneity of the Mac-1 expression on peripheral blood neutrophils in patients with different types of epithelial ovarian cancer. Immunobiology. 2016;221(2):323–32. doi:10.1016/j.imbio.2015.10.003.

    Article  CAS  PubMed  Google Scholar 

  39. Miao Y, Yan Q, Li S, Li B, Feng Y. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. Cancer Biomark. 2016;17(1):33–40. doi:10.3233/cbm-160614.

    Article  CAS  PubMed  Google Scholar 

  40. Ashrafganjoei T, Mohamadianamiri M, Farzaneh F, Hosseini MS, Arab M. Investigating preoperative hematologic markers for prediction of ovarian cancer surgical outcome. Asian Pac J Cancer Prev. 2016;17(3):1445–8.

    Article  PubMed  Google Scholar 

  41. Yildirim M, Demir Cendek B, Filiz Avsar A. Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Molecular Clin Oncol. 2015;3(2):317–21. doi:10.3892/mco.2014.481.

    Google Scholar 

  42. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.

    Article  CAS  PubMed  Google Scholar 

  43. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411–6. doi:10.1158/0008-5472.can-10-2583.

    Article  CAS  PubMed  Google Scholar 

  44. Zhang P, Zong Y, Liu M, Tai Y, Cao Y, Hu C. Prediction of outcome in breast cancer patients using test parameters from complete blood count. Mol Clin Oncol. 2016;4(6):918–24. doi:10.3892/mco.2016.827.

    PubMed  PubMed Central  Google Scholar 

  45. Stotz M, Liegl-Atzwanger B, Posch F, Mrsic E, Thalhammer M, Stojakovic T, et al. Blood-based biomarkers are associated with disease recurrence and survival in gastrointestinal stroma tumor patients after surgical resection. PloS One. 2016;11(7):e0159448. doi:10.1371/journal.pone.0159448.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Ying HQ, Deng QW, He BS, Pan YQ, Wang F, Sun HL, et al. The prognostic value of preoperative NLR, d-NLR, PLR and LMR for predicting clinical outcome in surgical colorectal cancer patients. Med Oncol. 2014;31(12):305. doi:10.1007/s12032-014-0305-0.

    Article  PubMed  Google Scholar 

  47. Deng Q, He B, Liu X, Yue J, Ying H, Pan Y, et al. Prognostic value of pre-operative inflammatory response biomarkers in gastric cancer patients and the construction of a predictive model. J Transl Med. 2015;13:66. doi:10.1186/s12967-015-0409-0.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PloS One. 2014;9(6):e101119. doi:10.1371/journal.pone.0101119.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014;23(1):31–9. doi:10.1016/j.suronc.2013.12.001.

    Article  PubMed  Google Scholar 

  50. Bugada D, Allegri M, Lavand’homme P, De Kock M, Fanelli G. Inflammation-based scores: a new method for patient-targeted strategies and improved perioperative outcome in cancer patients. BioMed Res Int. 2014;2014:142425. doi:10.1155/2014/142425.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Experimental Surgery and Surgical Research N.S.Christeas, Medical School, National and Kapodistrian University of Athens, 15B Agiou Thoma str Goudi, 115 23, Athens, Greece

    Anastasia Prodromidou, Panagiotis Andreakos, Charalampos Kazakos, Dimitrios Eftimios Vlachos, Despina Perrea & Vasilios Pergialiotis

Authors
  1. Anastasia Prodromidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Panagiotis Andreakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Charalampos Kazakos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dimitrios Eftimios Vlachos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Despina Perrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Vasilios Pergialiotis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anastasia Prodromidou.

Additional information

Responsible Editor: Liwu Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Prodromidou, A., Andreakos, P., Kazakos, C. et al. The diagnostic efficacy of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in ovarian cancer. Inflamm. Res. 66, 467–475 (2017). https://doi.org/10.1007/s00011-017-1026-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00011-017-1026-6

Keywords

Search

Navigation